Tighter REMS For Zohydro ER Still Insufficient For FDA Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anesthetic and Analgesic Drug Products Advisory Committee wants Risk Evaluation and Mitigation Strategies enhanced for all extended-release/long-acting opioids as it recommends 11-2, one abstention, against approval of Zogenix’s single-entity hydrocodone product.
You may also be interested in...
Will Aducanumab Join List Of Drugs Approved By US FDA Over Advisory Committee Opposition?
A look at drugs the agency approved despite an advisory committee vote not to do so and how they compare to Biogen’s Alzheimer’s disease drug aducanumab.
Zohydro Approval Haunts FDA Panelist At Vantrela Meeting
Teva's comparative data suggesting its Vantrela is less attractive to abusers validates advisory committee recommendation in 2012 against Zohydro's approval, advisory committee member says.
FDA's Opioid Regret? Skipping Another Zohydro Meeting, Califf Says
Agency addressed post-marketing concerns raised by advisory committee, Commissioner tells Senate, but should have returned to get panel's blessing.